Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis

dc.creator	Rule, S
dc.creator	Dreyling, M
dc.creator	Goy, A
dc.creator	Hess, G
dc.creator	Auer, R
dc.creator	Kahl, B
dc.creator	Hernández-Rivas, J-Á
dc.creator	Qi, K
dc.creator	Deshpande, S
dc.creator	Parisi, L
dc.creator	Wang, M
dc.date	2022-03-08T10:53:42Z
dc.date	2022-03-08T10:53:42Z
dc.date	2019-05-01
dc.date.accessioned	2022-05-26T21:09:41Z
dc.date.available	2022-05-26T21:09:41Z
dc.identifier	0390-6078
dc.identifier	http://hdl.handle.net/10026.1/18912
dc.identifier	10.3324/haematol.2018.205229
dc.identifier	1592-8721
dc.identifier.uri	http://localhost:8080/xmlui/handle/CUHPOERS/228964
dc.format	e211 - e214
dc.language	en
dc.language	en
dc.publisher	Ferrata Storti Foundation (Haematologica)
dc.relation	ISSN:0390-6078
dc.relation	E-ISSN:1592-8721
dc.rights	2022-03-09
dc.rights	Not known
dc.title	Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis
dc.type	Journal Article

Files in this item

Files	Size	Format	View
8911-Article Text-63824-1-10-20200724.pdf	553.8Kb	application/pdf	View/Open